Needham & Company LLC Forecasts Strong Price Appreciation for Establishment Labs (NASDAQ:ESTA) Stock

Establishment Labs (NASDAQ:ESTA) had its price target lifted by equities research analysts at Needham & Company LLC from $84.00 to $86.00 in a research report issued on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 9.85% from the company’s previous close.

Other equities analysts have also recently issued research reports about the stock. BTIG Research increased their price objective on shares of Establishment Labs from $81.00 to $86.00 and gave the stock a “buy” rating in a research report on Wednesday, December 31st. Mizuho upped their price target on Establishment Labs from $85.00 to $90.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. Citigroup raised their price objective on Establishment Labs from $62.00 to $75.00 and gave the company a “neutral” rating in a research note on Thursday, December 11th. Canaccord Genuity Group boosted their price objective on Establishment Labs from $72.00 to $85.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Finally, JPMorgan Chase & Co. upped their target price on Establishment Labs from $71.00 to $80.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 17th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $86.29.

Establishment Labs Stock Performance

Shares of ESTA stock opened at $78.29 on Tuesday. The firm has a 50 day moving average of $71.06 and a 200-day moving average of $57.87. The company has a market cap of $2.28 billion, a price-to-earnings ratio of -44.99 and a beta of 0.99. The company has a quick ratio of 2.10, a current ratio of 3.33 and a debt-to-equity ratio of 15.06. Establishment Labs has a 52 week low of $26.56 and a 52 week high of $83.31.

Establishment Labs (NASDAQ:ESTA) last released its earnings results on Tuesday, February 24th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.13. The company had revenue of $64.62 million for the quarter, compared to the consensus estimate of $63.80 million. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 197.22%. Establishment Labs’s quarterly revenue was up 45.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.19) EPS. On average, equities analysts forecast that Establishment Labs will post -2.41 earnings per share for the current year.

Hedge Funds Weigh In On Establishment Labs

A number of hedge funds have recently bought and sold shares of the company. Simplify Asset Management Inc. purchased a new stake in shares of Establishment Labs during the 3rd quarter worth approximately $1,555,000. Tejara Capital Ltd grew its holdings in Establishment Labs by 31.2% during the third quarter. Tejara Capital Ltd now owns 102,494 shares of the company’s stock valued at $4,201,000 after purchasing an additional 24,386 shares during the period. Woodson Capital Management LP increased its position in Establishment Labs by 113.3% in the third quarter. Woodson Capital Management LP now owns 480,000 shares of the company’s stock worth $19,675,000 after buying an additional 255,000 shares during the last quarter. Hood River Capital Management LLC raised its stake in shares of Establishment Labs by 138.2% in the second quarter. Hood River Capital Management LLC now owns 53,124 shares of the company’s stock valued at $2,269,000 after buying an additional 30,825 shares during the period. Finally, Affinity Asset Advisors LLC lifted its position in shares of Establishment Labs by 19.6% during the 2nd quarter. Affinity Asset Advisors LLC now owns 334,863 shares of the company’s stock valued at $14,302,000 after buying an additional 54,863 shares during the last quarter. 72.91% of the stock is owned by hedge funds and other institutional investors.

Establishment Labs News Summary

Here are the key news stories impacting Establishment Labs this week:

• Positive Sentiment: Q4 results beat expectations — EST A reported EPS of ($0.09) vs. a ($0.22) consensus and revenue of $64.62M (+45% y/y). Revenue beat and margin improvement were driver-positive for sentiment. Press Release
• Positive Sentiment: 2026 revenue guidance raised — Company provided FY2026 revenue guidance of $264.0M–$266.0M and is targeting at least 25% revenue growth, signaling continued top-line momentum. MSN Article
• Positive Sentiment: Multiple analyst upgrades/price-target raises — Stephens ($85→$90, overweight), Mizuho ($90→$100, outperform), BTIG ($86→$88, buy) and Needham ($84→$86, buy) boosted targets, reflecting bullish analyst views on growth trajectory. Benzinga Analyst Rundown
• Neutral Sentiment: Leadership transition announced — Company disclosed a leadership change intended to support the next growth phase; could be positive if execution steadies but creates short-term uncertainty. Yahoo Finance
• Neutral Sentiment: Full earnings materials and call transcript available — Analysts and investors can review details and management commentary to assess margin trajectory and M&A/R&D plans. Earnings Call Transcript
• Negative Sentiment: Company remains unprofitable — EST A reported a negative net margin (~-43%) and negative ROE; consensus still models negative EPS for the fiscal year, highlighting path to consistent profitability is not yet clear. Zacks
• Negative Sentiment: Short-term selling pressure despite positives — intraday volume has spiked above average while the stock trades down, suggesting some investors are booking gains or reacting to remaining execution/earnings risk. Benzinga

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.